Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/1553846/000155837021003168/rdhl-20201231x20f.htm
March 2023
March 2023
March 2023
March 2023
February 2023
February 2023
February 2023
February 2023
January 2023
January 2023
Please wait while we load the requested 20-F report or click the link below:
https://last10k.com/sec-filings/report/1553846/000155837021003168/rdhl-20201231x20f.htm
Compare this 20-F Annual Report to its predecessor by reading our highlights to see what text and tables were removed , added and changed by Redhill Biopharma Ltd..
Redhill Biopharma Ltd.'s Definitive Proxy Statement (Form DEF 14A) filed after their 2021 10-K Annual Report includes:
Financial Statements, Disclosures and Schedules
Inside this 20-F Annual Report
Material Contracts, Statements, Certifications & more
Redhill Biopharma Ltd. provided additional information to their SEC Filing as exhibits
Ticker: RDHL
CIK: 1553846
Form Type: 20-F Annual Report
Accession Number: 0001558370-21-003168
Submitted to the SEC: Thu Mar 18 2021 7:00:46 AM EST
Accepted by the SEC: Thu Mar 18 2021
Period: Thursday, December 31, 2020
Industry: Pharmaceutical Preparations